

Research Article

Evaluation of *Apolipoprotein e4* allele as Susceptible Factor for Neurodegenerative Diseases among Eastern Indians

Dipanwita Sadhukhan¹; Smriti Mishra¹; Priyanka Mukherjee¹; Atanu Biswas²; Subhra Prakash Hui³; Tapas Kumar Banerjee¹; Arindam Biswas¹

¹Molecular Biology & Clinical Neuroscience Division, National Neurosciences Centre, Calcutta, Kolkata, India

²Institute of Post graduate of Medical Education & Research and Bangur Institute of Neurosciences, Kolkata, India

³S.N Pradhan Centre for Neurosciences, University of Calcutta, Kolkata, India

***Corresponding author: Arindam Biswas**

Molecular Biology & Clinical Neuroscience Division, National Neurosciences Centre, Calcutta, Peerless Hospital (2nd floor) 360, Panchasayar, Kolkata 700094, India.

Email: thisisarindam@gmail.com

Received: October 18, 2023

Accepted: November 20, 2023

Published: November 27, 2023

Introduction

The Apolipoprotein E (ApoE) protein has a crucial role in lipid and cholesterol flux in the central nervous system [1]. Among its three major human isoforms, ApoE2, ApoE3, and ApoE4, *APOE4* is considered as one of the most potent risk factors for the development of neurological disorders. The presence of two arginine at the 112th and 158th positions in the *APOE4* protein provides it with an enhanced lipid binding property with reduced stability rendering pathogenicity than other isoforms.

Neuronal death in neurodegenerative diseases is often associated with abnormal protein accumulation, immune system activation, neuroinflammation and blood-brain barrier disruption. In Alzheimer's Disease (AD) pathology, *APOE* polymorphisms with the combined effect of sex, age, diet, and physical exercise, have a major effect on astrocytic and microglial function and microglial dynamics, synaptic function, amyloid- β load, tau pathology, autophagy, and cell-cell communication [2]. As

Abstract

Background & Objectives: Apolipoprotein E (ApoE) and age have been identified as the major risk factors for several neurodegenerative disorders. Among the three major isoforms (*ApoE2*, *ApoE3* & *ApoE4*) of *APOE*, *ApoE4* often shows ethnicity dependent association with neurodegenerative diseases. In the present study, we aim to determine the *e4* allele/genotype frequency among the different neurodegenerative disorders and their correlation with several demographic and clinical parameters from eastern India.

Methods: A total of 826 individuals were recruited for this study which includes 128 PD-MCI, 144 PDD, 90 DLB, 114 FTD, 94 AD and 256 unrelated neurologically controls from eastern India. Subjects were analysed for *APOE* genotype (*E2*, *E3* and *E4*) by PCR-RFLP techniques and Sanger sequencing.

Results: The *APOE4* allele was significantly associated with each of the disease subtypes, selected for the study ($P=0.016$ to 0.000), while *e3* allele was predominant among controls. Further stratification of subjects identified significant overrepresentation of (a) positive family history for FTD ($P=0.0414$) & AD ($P=0.029$) and (b) early age at onset of for PDD ($P=0.0316$) and FTD ($P=0.0034$) among the *e4* allele carriers. Furthermore, lowering of BMSE score was also observed among the *e4* allele carriers of AD subjects ($P=0.0324$).

Conclusion: There is a significant association of *APOE4* allele with different neurodegenerative diseases influencing lowering of age at onset, BMSE score and positive family history among ethnic Bengali population of eastern India.

Keywords: *APOE*; Neurodegenerative diseases; Indians

a result, *APOE4* carriers often show a greater A β deposition both in quantity and density compared to non-*APOE4* carriers. Similarly, in Parkinson's Disease (PD), an increase in alpha-synuclein aggregate formation is found to be influenced by the *APOE4* genotype [3]. However, studies showed incongruities in this regard suggesting that *APOE* polymorphisms may result in a higher risk of cognitive impairment than motor deterioration. In Lewy body dementia, it also has distinct roles in microglia-associated alpha-synuclein clearance in the midbrain [4]. A number of genetic association studies also highlighted increased disease risk for *e4* alleles in frontotemporal dementia [5].

Although *APOE* plays a significant role in several central nervous system pathologies which are mostly complex in nature, the genetic association data often appear to be inconsistent due to differences in *APOE* allele frequencies across ethnic populations. In India, a number of genetic studies have been

performed in neurodegenerative disorders considering either one or few disease types at a time. However, the results are conflicting and may be influenced by with limited number of study subjects and mutiethnicity. Therefore, the present study aims to evaluate the frequency of APOE isoforms in several neurodegenerative diseases in a relatively larger sample representing the ethnic Bengali population of Eastern India.

Materials and Methods

Study Subjects

A total of 570 patients clinically diagnosed with neurodegenerative disorders [128 Parkinson's disease with mild cognitive impairment (PD-MCI), 144 Parkinson's Disease with Dementia (PDD), 90 Dementia with Lewy body (DLB), 114 Frontotemporal Dementia (FTD) and 94 Alzheimer's Disease (AD)] by clinicians were recruited from Eastern India in this study with their written informed consent as per guidelines of Indian Council of Medical Research (ICMR). Patients were diagnosed following standard diagnosis criteria. In addition, 256 age and ethnicity matched unrelated healthy individuals with no personal or family history of neurodegenerative diseases and/ or any other neurological symptoms were also recruited as controls in the present study from Kolkata. Bengali version of Mini Mental State Examination (BMSE) scale was used for primary tool during evaluation [6]. The diagnostic labelling was done by trained neurologists (AB and TKB). Diagnosis was performed using standard diagnostic criteria (MDS task force criteria for PD-MCI [7] and PDD [8], FTD by FTD Consortium criteria [9], DLB by DLB consortium criterion – fourth consensus [10] and AD by NIA-AA criteria [11]. The demographic details of patients are described in Table 1.

Table 1: Demographic details of studied population.

| Category | Male: Female | Familial: Sporadic | Early onset: Late onset | Age at onset ± SD | BMSE ± SD |
|-----------------|--------------|--------------------|-------------------------|-------------------|------------|
| PD-MCI (n=128) | 90: 38 | 32: 96 | 38: 90 | 55.54±15.43 | 21.95±6.13 |
| PDD (n=144) | 100: 44 | 32: 112 | 26: 118 | 60.89±12.94 | 20.23±7.39 |
| DLB (n=90) | 64: 26 | 24: 66 | 16: 74 | 60.65±10.45 | 15.60±8.98 |
| FTD (n=114) | 76: 38 | 20: 94 | 24: 90 | 55.77±10.41 | 15.15±8.67 |
| AD (n=94) | 52: 42 | 48: 46 | 26: 68 | 58.30±9.84 | 14.04±6.91 |
| CONTROL (n=256) | 174: 82 | Not applicable | Not applicable | Not applicable | ≥26 |

*PD - MCI: Parkinson's disease with mild cognitive impairment; PDD: Parkinson's disease with dementia; DLB: Dementia with Lewy body; FTD: Frontotemporal dementia; AD: Alzheimer's disease; SD: Standard deviation; Early onset ≤50 years; Late onset >50 years; BMSE: Bengali version of Mini Mental State Examination.

Table 2: Allele & Genotype frequency of APOE among different neurodegenerative diseases.

| Study Subjects | Genotype frequency | | | | | Allele frequency | | | P-Value | Odds ratio (95% CI) | |
|-----------------|--------------------|---------------|-----------------|----------------|----------------|------------------|-----------------|----------------|----------|----------------------------|---------------------------|
| | E2/E3 | E2/E4 | E3/E3 | E3/E4 | E4/E4 | E2 | E3 | E4 | | | |
| CONTROL (n=256) | 32 (0.1250) | 0 (0.00) | 186 (0.7265) | 34 (0.1328) | 4 (0.0156) | 32 (0.0625) | 438 (0.8554) | 42 (0.0820) | Referent | | |
| PD-MCI (n=128) | 2 (0.0156) | 4 (0.0312) | 92 (0.7187) | 28 (0.2187) | 2 (0.0156) | 6 (0.0234) | 214 (0.8359) | 36 (0.1406) | | E4 vs Others: 0.016 | 1.81 (1.14-2.94) |
| PDD (n=144) | 6 (0.0416) | 0 (0.0) | 84 (0.5833) | 48 (0.3333) | 6 (0.0416) | 6 (0.0208) | 222 (0.7708) | 60 (0.2083) | | E4 vs Others: 0.000 | 2.94 (1.93-4.50) |
| DLB (n=90) | 4 (0.0444) | 0 (0.0) | 34 (0.3777) | 32 (0.3555) | 20 (0.2222) | 4 (0.0222) | 104 (0.5777) | 72 (0.4000) | | E4 vs Others: 0.000 | 7.46 (4.83-11.52) |
| FTD (n=114) | 8 (0.0655) | 2 (0.0163) | 68 (0.5573) | 38 (0.3114) | 6 (0.0491) | 10 (0.0409) | 182 (0.7459) | 52 (0.2131) | | E4 vs Others: 0.000 | 3.03 (1.95- 4.70) |
| AD (n=94) | 2 (0.0212) | 2 (0.0212) | 14 (0.1489) | 62 (0.6595) | 14 (0.1489) | 4 (0.0212) | 92 (0.4839) | 92 (0.4893) | | E4 vs Others: 0.000 | 10.72 (7.00-16.42) |

Table 3: Frequency of APOE4 carriers among different neurodegenerative disorders.

| Diagnosis | Subjects (n) | E4 Carriers (n) | % of Subjects | **P value | Relative Risk (95% CI) | P value |
|-----------|--------------|-----------------|---------------|------------|------------------------|------------|
| PD-MCI | 128 | 34 | 26.56% | 0.0081 | 1.79 (1.186–2.699) | 0.0055 |
| PDD | 144 | 54 | 37.5% | <0.00001. | 2.53 (1.760–3.626) | <0.0001 |
| DLB | 90 | 52 | 57.78% | <0.00001. | 3.89 (2.763–5.482) | <0.0001 |
| AD | 94 | 78 | 82.98% | <0.00001. | 5.59 (4.110–7.602) | <0.0001 |
| FTD | 122 | 46 | 37.70% | <0.00001. | 2.54 (1.752–3.683) | <0.0001 |
| Controls | 256 | 38 | 14.84% | References | References | References |

Collection of Blood Samples and Genomic DNA Preparation

10 mL of peripheral blood samples were collected in EDTA vials from patients and controls. Genomic DNA was prepared from fresh whole blood by conventional salting out method using sodium perchlorate followed by isopropanol precipitation [12] and dissolved in TE (10 mM Tris- HCl, 0.1 mM EDTA, pH 8.0) and stored at 4°C.

Polymerase Chain Reaction (PCR), Restriction Fragment Length Polymorphism (RFLP) Analysis

APOE genotypes were determined by Polymerase Chain Reaction (PCR) and restriction fragment length polymorphism techniques. The amplicon which was generated using specific primer pair was subjected to enzymatic digestions for 3 hours at 37°C with 1 U of the AflIII (New England Biolabs, Ipswich) and HaeII (New England Biolabs, Ipswich) independently. The digested products were separated on a 6% polyacrylamide gel and analysed further after visualization in a Gel documentation system (BIO-RAD, USA).

Statistical Analysis

Demographic and cognitive parameters were analysed using Mann Whitney U test and Fisher exact test.

Frequency of APOE alleles among neurodegenerative disorder subgroups was calculated with healthy controls as a reference group, using Fisher's exact test.

Relative Risk was calculated using the MedCalc statistical software. The probability level of ≤0.05 was considered statistically significant.

Results

Frequency of APOE4 in Disease Subgroups

The APOE SNPs, rs429358 and rs7412, which encode for the polymorphisms $\epsilon 2$, $\epsilon 3$, and $\epsilon 4$ were screened in 570 patients with various neurodegenerative disorders against 256 ethnically matched controls. All APOE alleles were within Hardy-Weinberg equilibrium in both the patients and control groups. Table 2 shows the allele and genotype frequencies of APOE variants in different disease types. For the APOE4 allele, a significant association with PD-MCI, PDD, DLB, FTD and AD were observed in our study cohorts ($P=0.016$ for PD-MCI and 0.000 for rest). The highest relative risk was observed for the AD group ($RR=5.59$; $95\% CI: 4.44 - 7.60$; $P<0.0001$) followed by DLB ($RR=3.89$), FTD ($RR=2.54$), PDD ($RR=2.53$) and PD-MCI ($RR=1.79$) (Table 3). In contrast, the $\epsilon 3$ allele was the predominant one in control group.

Comparison of Demographic Features and Cognitive Status

Next, we compared the demographic features like age at disease onset, positive family history, and gender between carriers and non-carriers of APOE E4 variant in each of the disease sub-type. A significant lowering of age at onset for PDD (56.85 years vs 63.08 years; $P=0.0316$) and FTD (54.09 years vs 58.79 years; $P=0.0034$) groups was observed for E4 carriers, while the presence of positive family history for FTD ($P=0.0414$) and AD cases ($P=0.029$) show significant correlation for the same (Table 4).

Table 4: Comparison of clinical parameters between E4 carriers and E4 noncarriers.

| A General Comparison Between E4 carriers and non-carrier's cases | | | |
|--|-----------------------------------|-----------------------------------|---------------|
| PD-MCI (n=128) | E4 carriers (n=34) | E4 non-carriers (n= 94) | P value |
| Age at disease onset (years), mean \pm SD | 54.68 \pm 18.81 | 55.04 \pm 14.48 | 0.4972 |
| Positive Family History, n (%) | 10(29.41%) | 22(23.40%) | 0.4956 |
| Male, n (%) | 28(82.35%) | 62(65.95%) | 0.0831 |
| BMSE, mean \pm SD | 18.41 \pm 7.33 | 21.43 \pm 3.6 | 0.238 |
| PDD (n= 144) | E4 carriers (n=54) | E4 non-carriers (n=90) | P value |
| Age at disease onset (years), mean \pm SD | 56.85\pm12.19 | 63.08\pm11.99 | 0.0316 |
| Positive Family History, n (%) | 12(22.22%) | 20(22.22%) | 1 |
| Male, n (%) | 34(62.96%) | 66(73.33%) | 0.1976 |
| BMSE, mean \pm SD | 18 \pm 9.18 | 21.04 \pm 7.13 | 0.526 |
| DLB (n= 90) | E4 carriers (n=38) | E4 non-carriers (n=52) | P value |
| Age at disease onset (years), mean \pm SD | 60.95 \pm 11.41 | 60.19 \pm 9.58 | 0.9362 |
| Positive Family History, n (%) | 14(26.92%) | 10(26.31%) | 1 |
| Male, n (%) | 38(73.08%) | 26(68.42%) | 0.6455 |
| BMSE, mean \pm SD | 13.69 \pm 9.37 | 17.17 \pm 8.9 | 0.2168 |
| FTD (n= 122) | E4 carriers (n=46) | E4 non-carriers (n=76) | P value |
| Age at disease onset (years), mean \pm SD | 54.09\pm8.78 | 58.79\pm6.47 | 0.0034 |
| Positive Family History, n (%) | 12(26.09%) | 8(10.53%) | 0.0414 |
| Male, n (%) | 32(69.57%) | 44(57.89%) | 0.2484 |
| BMSE, mean \pm SD | 14.83 \pm 8.37 | 18.33 \pm 7.76 | 0.2318 |
| AD (n= 94) | E4 carriers (n=78) | E4 non-carriers (n=16) | P value |
| Age at disease onset (years), mean \pm SD | 58.88 \pm 10.00 | 55.75 \pm 9.29 | 0.1565 |
| Positive Family History, n (%) | 44(56.4%) | 4(25%) | 0.029 |
| Male, n (%) | 42(53.84%) | 10(62.5%) | 0.59 |
| BMSE, mean \pm SD | 8.67\pm4.85 | 14\pm6.93 | 0.0324 |

BMSE: Bengali version of Mini Mental State Examination

Table 5: Frequency distribution of APOE4 allele as reported in Indian studies on neurodegeneration.

| Disease sub-types | Geographical Location | Study subjects | Frequency of e4 allele | Comments | References |
|-------------------|--------------------------|--------------------------------|------------------------------------|---|------------|
| PD | East India Kolkata | Patients:302 Controls:302 | Patients: 0.015 Controls: 0.084 | e4 allele increased the disease risk | [19] |
| | North India (Delhi) | Patients:70 Controls: 100 | Patients: 0.160 Controls: 0.080 | e4 allele increased the disease risk | [20] |
| MCI | South India (Bangalore) | Patients: 87 Control: 138 | Patients: 0.285 Controls: 0.177 | e4 allele increased the disease risk | [15] |
| DLB | South India (Bangalore) | Patients: 12 Controls: 138 | Patients: 0.208 Controls: 0.177 | The APOE e4 allele remained ineffectual in modulating disease risk | [15] |
| FTD | South India (Bangalore) | Patients: 127 Controls: 138 | Patients: 0.158 Controls: 0.177 | Not associated with disease risk | [15] |
| FTLD | East India (Kolkata) | Patient: 81 Controls: 269 | Patients: 0.148 Controls: 0.106 | Not associated with disease risk | [21] |
| DLB & FTD | South India (Bangalore) | Patients: 44 Controls: 195 | Patients: 0.079 Control:0.079 | Not associated with disease risk | [16] |
| AD | Western India (Mumbai) | Patients: 49 Controls: 100 | Patients: 0.190 Controls: 0.085 | Associated with AD | [22] |
| | North India (Delhi) | Patients: 29 Controls: 76 | Patients: 0.290 Controls: 0.092 | Associated with AD | [23] |
| | North India (Delhi) | Patients: 74 Controls: 113 | Patients: 0.270 Controls: 0.066 | Associated with AD | [24] |
| | South India (Bangalore) | Patients: 243 Controls: 164 | Patients: 0.240 Controls: 0.076 | Associated with AD | [25] |
| | North India (Delhi) | Patients: 70 Controls: 75 | Patients: 0.314 Controls: 0.073 | Associated with AD | [26] |
| | North India (Chandigarh) | Patients: 44 Controls: 46 | Patients: 0.390 Controls: 0.000 | Increased CSF tau protein levels in AD patients with APOE-e4 allele | [27] |
| | South India (Bangalore) | Patients: 137 Controls: 195 | Patients: 0.210 Controls: 0.079 | Associated with AD | [16] |
| | North India (Delhi) | Patients: 14 Controls: 46 | Patients: 0.430 Controls: 0.110 | Associated with AD | [28] |
| | South India (Bangalore) | Patients: 209 Controls: 193 | Patients: 0.469 Controls: 0.166 | Associated with AD | [29] |
| | East India (Kolkata) | Patients: 115 Controls: 162 | Patients: 0.096 Controls: 0.105 | APOE-e4 & C allele of rs1800795 together presented with early onset | [30] |
| | South India (Bangalore) | Control: 156 Patient:138 | Patients: 0.394 Controls: 0.177 | The APOE-e4 allele increased the risk for AD | [15] |

As mentioned in Table 1, irrespective of *APOE4* status a lowering of BMSE score *i.e* <25 (referring overall cognitive status) was observed in our patient cohort with different clinical diagnosis. However, after further stratification of subjects according to E4 isoform followed by an intra-group comparison, a significant lowering in BMSE score for AD ($P=0.0324$) but not for the other conditions was observed between E4 carriers and non-carriers.

Discussion

Identification of population-specific genetic risk variants in complex neurodegenerative diseases has long been reported in different studies. However, the major gene of interest is APOE across the world population showing ethnicity and disease specific association. In this present study, we observed an overrepresentation of APOE e4 allele in AD, PD, PD-MCI, DLB and FTD cases in ethnic Bengali population. Our data corroborates with previous Indian reports on PD, MCI and AD but is at variance with the other studies on DLB, FTD and FTLD (Table 5).

AD and PD cases are often been categorized into early-onset or late-onset cases, as age is an independent risk factor for both. Recent evidences suggest that although the APOE2 allele decreases late onset AD (LOAD) risk, the expression of one and two E4 allele increases the disease risk to threefold and 9 to 15-fold, respectively [13]. However, no such findings were observed here which may be due to recruitment of only late-onset AD cases and small number of non-E4 carrying AD patients in study cohort as well. In contrast, APOE4 allele carriers showed an early age at onset for FTD and PDD cohort [5]. Our present data for PDD is consistent with a meta-analysis study in 2006 [14]. However, negative association was reported in an early report from South India on FTD [15,16]. The small number of samples and genetic divergence may be probable reasons for lack of consistency in the nature of association between two studies from India. The south Indian population is representative of the original Dravidians from Central and South India while Eastern Indians belong to the Indo-European (IE) lineage [17].

Evidences suggest that positive family history in neurodegenerative disorders explains the part of individual differences in risk and progression for the diseases and thus it is often correlated with genetic variants to determine its influence in disease pathology. Here, an intra group comparative study describing the correlation between APOE4 polymorphism and family history in different diseases as summarised in Table 4, revealed a link only for AD and FTD suggesting its potential for these diseases among the Eastern Indians. However, the absence of such in rest suggests the role of additional genes with equal or greater significance.

The progression of neurodegeneration is always accompanied by different degrees of cognitive decline. Diseases like AD, DLB, FTD manifest cognitive failure as an initial symptom while PD-MCI and PDD are developed in few PD patients over time. A number of earlier reports, on the basis of frequency differences between cases and controls, already stated the E4 allele to be correlated with higher prevalence of dementia in synucleinopathies and AD [13,18]. However, when we compared the raw scores according to genotype, except for AD, no other diseases showed differences in BMSE scores between carriers and non-carriers among the patient cohort. Our data is concordant with other national and international reports for AD, while it needs further confirmatory studies considering scores and further sub domain analysis to make a definite conclusion.

Conclusion

In conclusion, our findings demonstrate that the APOE4 allele increases the risk of AD, PDD, PD-MCI, DLB and FTD among ethnic Bengali populations from Eastern India. Additionally, it has a negative impact on cognitive status for AD while influencing the early age at onset for PDD and FTD. A positive correlation between family history and APOE4 was also identified for AD and FTD. It would also be interesting to study and correlate the impaired cognitive subdomains in different disease types with APOE genotypes in future studies.

Author Statements

Ethical Considerations

The study was approved by the Institutional Ethical Committee at Institute of Post Graduate Medical Education & Research, Kolkata and National Neurosciences Centre Calcutta, Kolkata. The Research Ethics Board expressed no ethical objections to the submitted research plan. All participants provided written consent to participate in the study after a full explanation of the study procedures.

Funding

Supported by grants from the Department of Science & Technology, Govt. of India, under Cognitive Science Research Initiative Programme (DST/CSRI-PDF/2021/12) and (SR/CSRI/PDF-32/2014 and DST/CSRI-P/2017/22).

Conflict of Interest

The authors declare no conflicts of interest.

Acknowledgement

The authors thank the patient, family members, and healthy individuals who participated in the study.

Data Availability Statement

The data described in this study are available from the corresponding author upon reasonable request.

References

- Husain MA, Laurent B, Plourde M. APOE and Alzheimer's disease: from lipid transport to physiopathology and therapeutics. *Front Neurosci.* 2021; 15: 630502.
- Stephen TL, Cacciottolo M, Balu D, Morgan TE, LaDu MJ, Finch CE, et al. APOE genotype and sex affect microglial interactions with plaques in Alzheimer's disease mice. *Acta Neuropathol Commun.* 2019; 7: 82.
- Irwin DJ, Lee VM, Trojanowski JQ. Parkinson's disease dementia: convergence of α -synuclein, tau and amyloid- β pathologies. *Nat Rev Neurosci.* 2013; 14: 626-36.
- Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, et al. APOE4 exacerbates α -synuclein pathology and related toxicity independent of amyloid. *Sci Transl Med.* 2020; 12: eaay1809.
- Koriath C, Lashley T, Taylor W, Druey R, Dimitriadis A, Denning N, et al. ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid- β copathology. *Alzheimers Dement (Amst).* 2019; 11: 277-80.
- Das SK, Banerjee TK, Mukherjee CS, Bose P, Biswas A, Hazra A, et al. An urban community-based study of cognitive function among non-demented elderly population in India. *Neurol Asia.* 2006; 11: 37-48.

7. Litvan I, Goldman JG, Tröster AI, Schmand BA, Weintraub D, Petersen RC, et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. *Mov Disord.* 2012; 27: 349-56.
8. Martinez-Martin P, Falup-Pecurariu C, Rodriguez-Blazquez C, Serrano-Dueñas M, Carod Artal FJ, Rojo Abuin JM, et al. Dementia associated with Parkinson's disease: applying the Movement Disorder Society Task Force criteria. *Parkinsonism Relat Disord.* 2011; 17: 621-4.
9. Rascovsky K, Hodges JR, Knopman D, Mendez MF, Kramer JH, Neuhaus J, et al. Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal dementia. *Brain.* 2011; 134: 2456-77.
10. McKeith IG, Boeve BF, Dickson DW, Halliday G, Taylor JP, Weintraub D, et al. Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. *Neurology.* 2017; 89: 88-100.
11. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr, Kawas CH, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement.* 2011; 7: 263-9.
12. Johns MB Jr, Paulus-Thomas JE. Purification of human genomic DNA from whole blood using sodium perchlorate in place of phenol. *Anal Biochem.* 1989; 180: 276-8.
13. Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. *Nat Rev Neurol.* 2019; 15: 501-18.
14. Huang X, Chen P, Kaufer DI, Tröster AI, Poole C. Apolipoprotein E and dementia in Parkinson disease: a meta-analysis. *Arch Neurol.* 2006; 63: 189-93.
15. Jairani PS, Aswathy PM, Gopala S, Verghese J, Mathuranath PS. Interaction with the MAPT H1H1 genotype increases dementia risk in APOE ϵ 4 carriers in a population of Southern India. *Dement Geriatr Cogn Disord.* 2016; 42: 255-64.
16. Bharath S, Purushottam M, Mukherjee O, Bagepally BS, Prakash O, Kota L, et al. Apolipoprotein E polymorphism and dementia: a hospital-based study from southern India. *Dement Geriatr Cogn Disord.* 2010; 30: 455-60.
17. Indian Genome Variation Consortium. The Indian Genome Variation database (IGVdb): A project overview. *Hum Genet.* 2005; 118: 1-11.
18. Tsuang D, Leverenz JB, Lopez OL, Hamilton RL, Bennett DA, Schneider JA, et al. APOE ϵ 4 increases risk for dementia in pure synucleinopathies. *JAMA Neurol.* 2013; 70: 223-8.
19. Pal P, Sadhukhan T, Chakraborty S, Sadhukhan S, Biswas A, Das SK, et al. Role of apolipoprotein E, cathepsin D, and brain-derived neurotrophic factor in Parkinson's disease: A study from Eastern India. *NeuroMolecular Med.* 2019; 21: 287-94.
20. Singh NK, Banerjee BD, Bala K, Mitrabasu DDAA, Dung Dung AA, Chhillar N. APOE and LRPAP1 gene polymorphism and risk of Parkinson's disease. *Neurol Sci.* 2014; 35: 1075-81.
21. Das G, Sadhukhan T, Sadhukhan D, Biswas A, Pal S, Ghosh A, et al. Genetic study on frontotemporal lobar degeneration in India. *Parkinsonism Relat Disord.* 2013; 19: 487-9.
22. Chandak GR, Sridevi MU, Vas CJ, Panikker DM, Singh L. Apolipoprotein E and presenilin-1 allelic variation and Alzheimer's disease in India. *Hum Biol.* 2002; 74: 683-93.
23. Luthra K, Tripathi M, Grover R, Dwivedi M, Kumar A, Dey AB. Apolipoprotein E gene polymorphism in Indian patients with Alzheimer's disease and vascular dementia. *Dement Geriatr Cogn Disord.* 2004; 17: 132-5.
24. Mansoori N, Tripathi M, Alam R, Luthra K, Ramakrishnan L, Parveen S, et al. IL-6-174 G/C and ApoE gene polymorphisms in Alzheimer's and vascular dementia patients attending the cognitive disorder clinic of the All India Institute of Medical Sciences, New Delhi. *Dement Geriatr Cogn Disord.* 2010; 30: 461-8.
25. Shankarappa BM, Kota LN, Purushottam M, Nagpal K, Mukherjee O, Viswanath B, et al. Effect of CLU and PICALM polymorphisms on AD risk: A study from south India. *Asian J Psychiatry.* 2017; 7: 7-11.
26. Singh NK, Chhillar N, Banerjee BD, Bala K, Mukherjee AK, Mustafa MD, et al. Gene-environment interaction in Alzheimer's disease. *Am J Alzheimers Dis Other Dement.* 2012; 27: 496-503.
27. Kandimalla RJ, Prabhakar S, Binukumar BK, Wani WY, Gupta N, Sharma DR, et al. Apo-E ϵ 4 allele in conjunction with A β 42 and tau in CSF: biomarker for Alzheimer's disease. *Curr Alzheimer Res.* 2011; 8: 187-96.
28. Kapur S, Sharad S, Kapoor M, Bala K. ApoE Genotypes: risk factor for Alzheimer's disease. *Indian academy of clinical medicine.* 2006; 7: 118-22.
29. Kota LN, Shankarappa BM, Shivakumar P, Sadanand S, Bagepally BS, Krishnappa SB, et al. Dementia and diabetes mellitus: association with apolipoprotein e4 polymorphism from a hospital in southern India. *Int J Alzheimers Dis.* 2012; 2012: 702972.
30. Chakraborty S, Joardar A, Roy S, Gangopadhyay G, Biswas A. ApoE ϵ 4 and IL-6-174G/C polymorphism may lead to early onset of Alzheimer's disease with atypical presentation. *Neurol India.* 2021; 69: 1228-33.